Civil and medical nuclear applications are not two different worlds. Over the time, the radiopharmaceutical companies became independent and have developed their own radionuclides production tools, including cyclotron networks enabling them to product the most common radionuclides such as Fluorine-18, Thallium-201, Iodine-123 or Indium-111.
But the radiopharmaceutical industry y largely depends on the reactors, all public, for the access to the longer half-life radionuclides.
The most common radionuclide, Technetium-99m is produced through a tool named generator, a separation system based on Molybdenum-99, weekly delivered to each NM department. Molybdenum-99 is a product of the decay chain of uranium and is obtained in reactors, together with Iiodine-131.
Presently, these reactors enable to produce also in industrial amounts, radionuclides such as Lutetium-177, Samarium-153 or Strontium-90. On the other hand, Lead-212 is originally a product extracted from the thorium decay chain, what we commonly call "nuclear waste".
Before concluding, we should not forget that nuclear medicine has benefited from all the improvements made by the civil nuclear industry in terms of radioprotection, waste management and transport.